Markets:

Overview

News

Currencies

International

Treasuries

Intercept Pharmaceuticals, Inc. - Common Stock (NQ:ICPT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intercept Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 09, 2021

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients ↗

November 15, 2021

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free...

Via Benzinga

86 Biggest Movers From Yesterday ↗

November 04, 2021

Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million....

Via Benzinga

Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

ICPT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Intercept Reports Narrower Q3 Loss; Raises Ocaliva Annual Sales Guidance ↗

November 03, 2021

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported Q3 sales of $92.8 million, up 17% Y/Y, surpassing the consensus of $83.02 million. Ocaliva net sales comprised U.S...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 23, 2021

Gainers Cara Therapeutics (NASDAQ:CARA) ...

Via Benzinga

58 Biggest Movers From Friday ↗

August 23, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter...

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

August 20, 2021

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021 ↗

August 20, 2021

Upgrades For Investors Bancorp Inc (NASDAQ:

Via Benzinga

Intercept Downgraded To Sell From Neutral At Goldman Sachs ↗

August 20, 2021

Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $10, down from $17, implying a 30% downside.

Via Talk Markets

10 Biggest Price Target Changes For Friday ↗

August 20, 2021

Raymond James boosted the price target on The Estée Lauder Companies Inc. (NYSE:

Via Benzinga

Return on Capital Employed Overview: Intercept Pharmaceuticals ↗

August 06, 2021

After pulling data from Benzinga Pro it seems like during Q2, Intercept Pharmaceuticals (NASDAQ:ICPT) earned $760.00 thousand, a 102.59% increase from the preceding quarter....

Via Benzinga

Intercept Pharmaceuticals, inc (ICPT) Q2 2021 Earnings Call Transcript ↗

July 30, 2021

ICPT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Intercept Pharmaceuticals: Q2 Earnings Insights ↗

July 29, 2021

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Earnings Outlook For Intercept Pharmaceuticals ↗

July 28, 2021

Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 27, 2021

Gainers Acutus Medical (NASDAQ:AFIB) sto...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021 ↗

July 19, 2021

The biotech can't seem to catch a break.

Via The Motley Fool

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury ↗

May 26, 2021

The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc’s (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 26, 2021

Wednesday morning, 20 companies set new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Ionis...

Via Benzinga

The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing ↗

May 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 25, 2021

Tuesday's morning session saw 16 companies set new 52-week lows. Noteworthy Points: The largest company in terms of market cap to set a new 52-week low was...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗

May 25, 2021

Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...

Via Benzinga

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal ↗

May 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intercept Pharmaceuticals, Inc. - Common Stock (NQ:ICPT)

Headline News about Intercept Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today